Dark

CLRB
Cellectar Biosciences INC NEW
stock NASDAQ

Market Open

Aug 4, 2026 3:51:15 PM EDT

2.62USD+1.946%(+0.05)29,966

2.19Bid 3.00Ask 0.81Spread

Pre-market

Aug 4, 2026 8:08:30 AM EDT

2.68USD+4.195%(+0.11)100

After-hours

Aug 3, 2026 4:00:30 PM EDT

2.66USD+3.502%(+0.09)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

08:30AM EST Cellectar to Participate in Fireside Chat at the H.C. Wainwright GlobeNewswire Inc

Dec 13, 2021

08:33AM EST Cellectar Presented Data From Its Ongoing Phase 2 CLOVER-1 Study Of Iopofosine I-131 At The 63rd ASH Annual Meeting And Exposition Benzinga

08:30AM EST Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma GlobeNewswire Inc

Dec 8, 2021

08:34AM EST Cellectar Biosciences Announces Poster Presentation At 63rd American Society For Hematology Annual Meeting And Exposition Dec. 11 Benzinga

08:30AM EST Cellectar Biosciences Announces Poster Presentation at the 63rd GlobeNewswire Inc

Nov 16, 2021

08:31AM EST Cellectar Biosciences Says Co's Iopofosine I-131 Exhibits Signals Of Efficacy In Phase 1 Study For Pediatric Brain And Solid Tumors Benzinga

08:30AM EST Cellectars Iopofosine I-131 Exhibits Signals of GlobeNewswire Inc

Nov 15, 2021

10:41AM EST Kazia Therapeutics Named John Friend, MD, as Chief Medical Officer Benzinga

Nov 8, 2021

08:43AM EST Cellectar Biosciences Q3 EPS $(0.10) Up From $(0.15) YoY Benzinga

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. GlobeNewswire Inc

Nov 2, 2021

08:30AM EDT Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief GlobeNewswire Inc

Oct 25, 2021

09:00AM EDT Cellectar Announces Innovative Concierge Service for Patients GlobeNewswire Inc

Sep 22, 2021

08:58AM EDT CLRB : Iopofosine I-131- External Beam Radiation Data Suggests Safety And Tolerability InRefractory Head And Neck Cancer RTTNews

08:33AM EDT Cellectar Biosciences Announces Completion Of Part A Portion Of Safety And Tolerability Study Of Iopofosine I-131 In Combination With External Beam Radiation Benzinga

08:30AM EDT Preliminary Data with Iopofosine I-131 in Combination with GlobeNewswire Inc

Sep 15, 2021

04:01PM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference: GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

11:55AM EDT Cellectar Receives $2M NIH Grant For Rare Lymphoma Study Benzinga

08:33AM EDT Cellectar Granted $2 Mln Phase II NIH SBIR Grant To Support Study Of Iopofosine I-131 In Waldenstrom's Macroglobulinemia RTTNews

08:31AM EDT Cellectar Awarded $2.0M Phase II NIH SBIR Grant To Support Pivotal Study Of Iopofosine I-131 In Waldenstrom's Macroglobulinemia Benzinga

08:30AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI). GlobeNewswire Inc

Aug 16, 2021

08:32AM EDT Cellectar Announces Manufacturing And Supply Agreement With Evergreen Theragnostics For CLR-131, Now Known As iopofosine I-131; Financial Terms Not Disclosed Benzinga

08:30AM EDT Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) GlobeNewswire Inc

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 9, 2021

08:39AM EDT Cellectar Biosciences Q2 EPS $(0.11) Up From $(0.26) YoY Benzinga

08:30AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2021 and provided a corporate update. GlobeNewswire Inc

Jul 16, 2021

10:14AM EDT UPDATE: Roth Capital On Cellectar Biosciences: Firm Highlights Collaboration With South Korean Biotech IntoCell To Develop New Phospholipid Drug Conjugates; Notes Other Collaboration With South Korean LegoChem Biosciences To Generate New Cancer Therapies Benzinga

10:13AM EDT Roth Capital Maintains Buy Rating On Cellectar Biosciences With $10 Price Target Benzinga

Jul 13, 2021

09:01AM EDT Cellectar Shares Move Higher; Co Announces Expansion Of Ongoing Collaboration Agreement With IntoCell; Terms Not Disclosed Benzinga

09:01AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has expanded its ongoing collaboration with IntoCell Inc., a biotechnology company based in South Korea. GlobeNewswire Inc

Jul 12, 2021

11:01AM EDT Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors Benzinga

08:37AM EDT Cellectar Announces Co-Development And Commercialization Collaboration With LegoChemBio RTTNews

08:34AM EDT Cellectar Announces Co-Development And Commercialization Collaboration With LegoChemBio For New Small Molecule Phospholipid Drug Conjugates; Financial Details Not Disclosed Benzinga

08:30AM EDT Cellectar Announces a Co-Development and Commercialization GlobeNewswire Inc

Jul 8, 2021

01:32PM EDT Cellectar Biosciences 13G Filing From Rosalind Advisors Shows 6% Stake In Co. Benzinga

08:33AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conference: GlobeNewswire Inc

Jun 24, 2021

08:30AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Dr. Asher Alban Chanan-Khan has been elected to its board of directors as an independent director. GlobeNewswire Inc

Jun 4, 2021

03:13PM EDT Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy Benzinga

09:16AM EDT Cellectar Presents Data in Waldenstrom's Macroglobulinemia in Poster at the 2021 American Society of Clinical Oncology Annual Meeting Benzinga

09:00AM EDT Cellectar Presents Data in Waldenstroms GlobeNewswire Inc

May 20, 2021

08:35AM EDT Cellectar Announces Poster Presentation Of CLR 131 Data In Waldenstrom's Macroglobulinemia At 2021 American Society of Clinical Oncology Annual Meeting Benzinga

08:30AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) Annual meeting to be held virtually June 4-8, 2021. GlobeNewswire Inc

May 14, 2021

09:00AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1x1 meetings at the following upcoming conference: GlobeNewswire Inc

May 10, 2021

08:31AM EDT Cellectar Biosciences Q1 EPS $(0.13) Up From $(0.42) YoY Benzinga

08:30AM EDT Initiated pivotal study of CLR 131 in Waldenstroms macroglobulinemia (WM)Received European Orphan Drug Designation for CLR 131 in WM GlobeNewswire Inc

Apr 27, 2021

08:45AM EDT Cellectar Biosciences Receives Formal Grant Of Patent Titled 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles' By Eurasian, Australian And Mexican Patent Authorities Benzinga

08:40AM EDT Cellectar Strengthens Global IP Position with Phospholipid Drug GlobeNewswire Inc

Mar 11, 2021

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conferences: GlobeNewswire Inc

Mar 9, 2021

09:18AM EST Cellectar Reports Was Granted Japanese Composition Of Matter Patent For Its Phospholipid-Ether Drug Conjugates Benzinga

09:00AM EST Cellectar Granted Japanese Composition of Matter Patent for its GlobeNewswire Inc

Mar 5, 2021

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will be available for 1x1 meetings at the following upcoming conferences: GlobeNewswire Inc

Mar 2, 2021

08:34AM EST Cellectar Biosciences FY20 EPS $(0.76), Up From $(1.84) YoY Benzinga

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2020 and provided a corporate update. GlobeNewswire Inc

Feb 10, 2021

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and CEO will present a company overview at the virtual 2021 BIO CEO & Investor Digital Conference to be held from February 16-18, 2021. GlobeNewswire Inc

Jan 27, 2021

08:43AM EST Cellectar Gets Orphan Drug Designation From EMA For CLR 131 In Waldenstrom's Macroglobulinemia RTTNews

08:37AM EST Cellectar Biosciences Reports Receives Orphan Drug Designation From European Commission For CLR 131 In Waldenstrom's Macroglobulinemia Benzinga

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the European Medicines Agency has adopted a positive opinion for CLR 131 orphan designation for the treatment of Waldenstroms Macroglobulinemia (WM). GlobeNewswire Inc

Jan 12, 2021

08:35AM EST Cellectar Initiates Pivotal Trial Of CLR 131 In Waldenstrom's Macroglobulinemia Benzinga

08:30AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the initiation of a pivotal trial for CLR 131 in Waldenstroms macroglobulinemia (WM). GlobeNewswire Inc

Dec 28, 2020

04:05PM EST Cellectar Biosciences Announces Closing of $24.5 Million GlobeNewswire Inc

Dec 23, 2020

02:31PM EST Mid-Afternoon Market Update: Bridgeline Digital Falls Following Q4 Earnings; Jaguar Health Shares Jump Benzinga

12:11PM EST Mid-Day Market Update: Crude Oil Rises 2%; Kubient Shares Plummet Benzinga

10:18AM EST Mid-Morning Market Update: Markets Mostly Higher; Paychex Tops Q2 Views Benzinga

08:39AM EST Cellectar Biosciences Announces Pricing Of $24.5M Offering At $1.35/Share Benzinga

08:39AM EST Cellectar Biosciences Announces Pricing of $24.5 Million GlobeNewswire Inc

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

05:28PM EST Cellectar Biosciences Announces Proposed Underwritten Public GlobeNewswire Inc

Dec 13, 2020

04:27PM EST The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics Benzinga

Nov 9, 2020

09:40AM EST Cellectar Biosciences Earlier Reported Q3 EPS $(0.15) Up From $(0.42) YoY Benzinga

08:49AM EST Cellectar Q3 Net Loss Attributable $3.9 Mln Or $0.15/Shr Vs Loss $3.9 Mln Or $0.42/Shr Last Year RTTNews

08:44AM EST Cellectar Biosciences, Inc.(NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the third quarter ended September 30, 2020 and provided a corporate update. GlobeNewswire Inc

Nov 5, 2020

09:10AM EST Cellectar Biosciences Reports CLR 131 Showed Prelim. Activity In Phase 1 Study For Pediatric Brain, Solid Tumors Benzinga

09:06AM EST Cellectar Biosciences Reports Co's CLR 131 Demonstrates Preliminary Activity In Phase 1 Study For Pediatric Brain And Solid Tumors Benzinga

Sep 10, 2020

08:00AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced James Caruso, president and CEO, will present at the following investor conferences in September and be available for 1x1 meetings: GlobeNewswire Inc

Sep 9, 2020

08:14AM EDT Cellectar Reports Data On CLR 131 Phase 2 CLOVER-1 Stuy In Triple Class Refractory Multiple Myeloma Patients; Reports A 'Clinically Meaningful 40% Overall Response Rate Was Observed' Benzinga

08:00AM EDT Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple GlobeNewswire Inc

Aug 17, 2020

10:07AM EDT Cellectar Presents Poster At AACR Virtual Meeting Titled 'ADVANCES IN MALIGNANT LYMPHOMA' Benzinga

10:01AM EDT Poster highlights the Phase 2a study data in relapsed or refractory lymphoplasmacytic lymphoma (LPL)/Waldenstroms macroglobulinemia (WM) GlobeNewswire Inc

Aug 11, 2020

04:52PM EDT Cellector Biosciences Files For A Mixed Shelf Offering Of Up To $100M Benzinga

Aug 10, 2020

08:30AM EDT Cellectar Biosciences Q2 EPS $(0.26) Beats $(0.30) Estimate Benzinga

08:00AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update. GlobeNewswire Inc

Aug 4, 2020

08:00AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the upcoming rescheduled International Symposium on Pediatric Neuro-Oncology (ISPNO) annual meeting taking place December 13-16 in Karuizawa, Japan. GlobeNewswire Inc

Jul 22, 2020

10:14AM EDT Cellectar Biosciences Granted European Patent Number EP3229810 Titled 'PHOSPHOLIPID ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Benzinga

Jul 21, 2020

08:00AM EDT Cellectar Biosciences, Inc.(NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a poster presentation at the upcoming American Association of Cancer Research (AACR) annual meeting being held virtually on August 17-19, 2020. GlobeNewswire Inc